Summary and general discussion 179 References 1. Hendriks JM, Gallagher C, Middeldorp ME, Lau DH, Sanders P. Risk factor management and atrial fibrillation. Europace. 2021;23(23 Suppl 2):ii52-ii60. 2. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2020;42(5):373-498. 3. VZinfo.nl. Hart- en vaatziekten | Leeftijd en geslacht. In: RIVM, editor. Den Haag: Ministerie van Volksgezondheid, Welzijn en Sport ( VWS (Ministerie van Volksgezondheid, Welzijn en Sport)); 2022. 4. Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH, et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2015;17(1):18-23. 5. Ghzally Y AI, Gerasimon G. Catheter Ablation. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470203/. 6. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. 7. ten Cate V, ten Cate H, Verheugt FWA. The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). Netherlands Heart Journal. 2016;24(10):574-80. 8. NVVC. Richtlijn Antitrombotisch beleid. Federatie Medisch Specialisten2016. 9. de Heide J, de Wit A, Bhagwandien RE, Assaf A, Gros-Bisdom J, van der Meer KC, et al. Efficacy and safety of direct oral anticoagulants in patients undergoing elective electrical cardioversion: A realworld patient population. Int J Cardiol. 2021;326:98-102. 10. De Heide J, Vroegh CJ, Bhagwandien RE, Wijchers SA, Szili-Torok T, Zijlstra F, et al. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation. J Interv Card Electrophysiol. 2018;53(3):341-6. 11. Ariyaratnam JP, Middeldorp M, Thomas G, Noubiap JJ, Lau D, Sanders P. Risk Factor Management Before and After Atrial Fibrillation Ablation. Card Electrophysiol Clin. 2020;12(2):141-54. 12. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159-69. 13. de Heide J, Kock-Cordeiro DBM, Bhagwandien RE, Hoogendijk MG, van der Meer KC, Wijchers SA, et al. Impact of undiagnosed obstructive sleep apnea on atrial fibrillation recurrence following catheter ablation (OSA-AF study). Int J Cardiol Heart Vasc. 2022;40:101014. 14. Lefebvre M-CD, St-Onge M, Glazer-Cavanagh M, Bell L, Kha Nguyen JN, Viet-Quoc Nguyen P, et al. The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study. Canadian Journal of Cardiology. 2016;32(2):169-76. 15. Porres-Aguilar M, Márquez MF, Arauz A. Factor XI inhibitors: The ongoing search for anticoagulation strategies in the prevention of arterial thromboembolism in cardiac and cerebrovascular disease. Int J Cardiol Heart Vasc. 2024;51:101388. 16. Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023;389(18):1660-71. 17. Shantsila E, Choi E-K, Lane DA, Joung B, Lip GYH. Atrial fibrillation: comorbidities, lifestyle, and patient factors. The Lancet Regional Health - Europe. 2024;37:100784. 18. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARRESTAF cohort study. J Am Coll Cardiol. 2014;64(21):2222-31. 19. Nguyen BO, Crijns H, Tijssen JGP, Geelhoed B, Hobbelt AH, Hemels MEW, et al. Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. Europace. 2022;24(6):910-20. 10
RkJQdWJsaXNoZXIy MTk4NDMw